{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:12:20Z","timestamp":1789711940277,"version":"4.0.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"suppl_5","funder":[{"DOI":"10.13039\/100000061","name":"National Institutes of Health National Institute of Dental and Craniofacial Research Fogarty International Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"National Institutes of Health National Institute of Dental and Craniofacial Research Fogarty International Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"National Institutes of Health National Institute of Dental and Craniofacial Research Fogarty International Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11,15]]},"DOI":"10.1093\/cid\/civ602","type":"journal-article","created":{"date-parts":[[2015,11,9]],"date-time":"2015-11-09T19:33:10Z","timestamp":1447097590000},"page":"S547-S553","source":"Crossref","is-referenced-by-count":3,"title":["Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali"],"prefix":"10.1093","volume":"61","author":[{"given":"Nicole E.","family":"Basta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoulaye","family":"Berthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awa Traor\u00e9 Eps","family":"Demb\u00e9l\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Onwuchekwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahamatou M.","family":"Boukary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Mabey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Findlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samba O.","family":"Sow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,11,9]]},"reference":[{"issue":"suppl 2","key":"key\n\t\t\t\t20171014005746_CIV602C1","first-page":"B13","article-title":"Epidemic meningitis due to group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution","volume":"27","year":"2009","journal-title":"Vaccine"},{"issue":"suppl 1","key":"key\n\t\t\t\t20171014005746_CIV602C2","first-page":"A97","article-title":"The Meningitis Vaccine Project","volume":"25","year":"2007","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014005746_CIV602C3","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0140-6736(03)13494-0","article-title":"Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries","volume":"361","year":"2003","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014005746_CIV602C4","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.vaccine.2008.11.092","article-title":"Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa","volume":"27","year":"2009","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014005746_CIV602C5","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1377\/hlthaff.2011.0328","article-title":"Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine","volume":"30","year":"2011","journal-title":"Health Affairs"},{"issue":"suppl 1","key":"key\n\t\t\t\t20171014005746_CIV602C6","first-page":"A101","article-title":"Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults","volume":"25","year":"2007","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014005746_CIV602C7","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1016\/j.vaccine.2012.08.004","article-title":"Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2\u201310 years: a phase II\/III double-blind randomized controlled trial","volume":"30","year":"2012","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014005746_CIV602C8","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","article-title":"Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014005746_CIV602C9","article-title":"Meningitis Vaccine Project. News digest 42. Quarter 4, 2014"},{"key":"key\n\t\t\t\t20171014005746_CIV602C10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (MenAfriVac\u00ae) on serogroup A meningococcal meningitis and carriage in Chad: a community study","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014005746_CIV602C11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3201\/eid2101.140256","article-title":"Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013","volume":"21","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20171014005746_CIV602C12","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity","volume":"56","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014005746_CIV602C13","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1186\/s12879-014-0663-4","article-title":"Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac","volume":"14","year":"2014","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20171014005746_CIV602C14","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.vaccine.2012.12.035","article-title":"Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt","volume":"31","author":"Dakar Discussion Group on Priorities for Research on Epidemic Meningococcal Disease in Africa;","year":"2013","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014005746_CIV602C15","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014005746_CIV602C16","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1365-3156.2007.01929.x","article-title":"Systematic review: impact of meningococcal vaccination on pharyngeal carriage of meningococci","volume":"12","year":"2007","journal-title":"Trop Med Int Health"},{"key":"key\n\t\t\t\t20171014005746_CIV602C17","article-title":"Polysaccharide vaccines for preventing serogroup A meningococcal meningitis","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20171014005746_CIV602C18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/archdischild-2013-303893","article-title":"Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination","volume":"98","year":"2013","journal-title":"Arch Dis Child"},{"key":"key\n\t\t\t\t20171014005746_CIV602C19","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1128\/CVI.05354-11","article-title":"Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood","volume":"18","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"RR-2","key":"key\n\t\t\t\t20171014005746_CIV602C20","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"key\n\t\t\t\t20171014005746_CIV602C21","article-title":"Changes to the meningococcal C conjugate (MenC) vaccine schedule 2013\u20132015","author":"Public Health England"},{"key":"key\n\t\t\t\t20171014005746_CIV602C22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/archdischild-2012-303103","article-title":"Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease","volume":"98","year":"2013","journal-title":"Arch Dis Child"},{"key":"key\n\t\t\t\t20171014005746_CIV602C23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","year":"2004","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014005746_CIV602C24","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1016\/j.vaccine.2013.07.083","article-title":"Effectiveness of meningococcal serogroup C vaccine programmes","volume":"31","year":"2013","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014005746_CIV602C25","article-title":"Global health observatory data repository. Number of suspected meningitis cases reported. Data by country.","author":"World Health Organization"},{"key":"key\n\t\t\t\t20171014005746_CIV602C26","article-title":"Global Alert and Response (GAR) epidemiological information. Meningitis season reports and weekly reports","author":"World Health Organization"},{"issue":"(suppl 5)","key":"key\n\t\t\t\t20171014005746_CIV602C27","first-page":"S578","article-title":"Higher tetanus toxoid immunity 2 years after PsA-TT introduction in Mali","volume":"61","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014005746_CIV602C28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"key\n\t\t\t\t20171014005746_CIV602C29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1128\/JCM.30.1.154-159.1992","article-title":"Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay","volume":"30","year":"1992","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171014005746_CIV602C30","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","year":"1969","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20171014005746_CIV602C31","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"key\n\t\t\t\t20171014005746_CIV602C32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","article-title":"Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15\u201325 years","volume":"27","year":"2009","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014005746_CIV602C33","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2014serum bactericidal antibody activity","volume":"23","year":"2005","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014005746_CIV602C34","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4161\/hv.19619","article-title":"Development of a group A meningococcal conjugate vaccine, MenAfriVac","volume":"8","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t20171014005746_CIV602C35","article-title":"Programme elargi de vaccination. Evaluation de la campagne de vaccination contre la meningite avec le vaccine MenAfriVac 2eme phase, dans les regions de Koulikoro, Segou et le district de Bamako au Mali en 2010","author":"Organisation mondiale de la sant\u00e9","year":"2011"},{"key":"key\n\t\t\t\t20171014005746_CIV602C36","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.vaccine.2014.04.052","article-title":"The impact of pre-existing antibody on subsequent immune responses to meningococcal A\u2013containing vaccines","volume":"32","year":"2014","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014005746_CIV602C37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/CVI.00008-07","article-title":"Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7","volume":"14","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"key\n\t\t\t\t20171014005746_CIV602C38","doi-asserted-by":"crossref","first-page":"e55486","DOI":"10.1371\/journal.pone.0055486","article-title":"Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20171014005746_CIV602C39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/trstmh\/tru167","article-title":"Sex-based differences in immune function and responses to vaccination","volume":"109","year":"2015","journal-title":"Trans R Soc Trop Med Hyg"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/61\/suppl_5\/S547\/20914504\/civ602.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:40:49Z","timestamp":1599784849000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/61\/suppl_5\/S547\/418449\/PopulationLevel-Persistence-of-Immunity-2-Years"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,9]]},"references-count":39,"journal-issue":{"issue":"suppl_5","published-online":{"date-parts":[[2015,11,9]]},"published-print":{"date-parts":[[2015,11,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/civ602","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,11,15]]},"published":{"date-parts":[[2015,11,9]]}}}